Hearing Date of Thalidomide Lawsuit in Germany announced

Food and Healthcare Press Releases Tuesday February 14, 2017 08:40
COLOGNE, Germany--14 Feb--PRNewswire/InfoQuest

60 years after the market launch of Contergan (active ingredient: thalidomide), the greatest pharmaceutical scandal in the Federal Republic of Germany continues to boil. A lawsuit will be heard in the Bonn Regional Court at 12:00 hrs on 15.2.2017 that is more explosive than appears at first sight.

The Contergan victim Andreas Meyer, who was born without arms or legs and is confined to a wheelchair, is suing the former member of the Management Board of the Contergan Foundation, Attorney Karl Schucht, for injunction and rectification.

In a letter to the members of the Family Affairs Committee of the German Federal Parliament, Schucht had asserted that Meyer, as an expert witness at a public hearing of the Committee, had publicly stated various untruths about events connected with the Contergan Foundation.

Meyer had said among other things that for 30 years the Contergan (thalidomide) manufacturer Grunenthal GmbH had had access to the medical files of the Contergan victims in the Contergan Foundation. In addition, Grunenthal had also paid the Foundation's medical experts.

In his letter, Schucht asserted to the contrary that Grunenthal had at no time had access to the medical files of the Contergan victims, but that the files were always kept by the Contergan Foundation. Further, he asserted that the experts of the Medical Commission were always paid from the funds of the Contergan Foundation.

Why so explosive? Because if Meyer wins the lawsuit it will mean that not only Schucht had told untruths to the members of Parliament. No, the Federal Government had also told untruths to Parliament.

Because the Federal Ministry of Family Affairs, which has been responsible for supervision of the Contergan Foundation since 1972, stated in a reply to a Minor Interpellation by the Parliamentary Group Die Linke that Schucht's letter also expressed the opinion of the Federal Government.

A pivotal question, according to Meyer, is the double role of Attorney Herbert Wartensleben who has also been invited as a witness by the Bonn Regional Court. From 1972 until the end of 2003, Wartensleben was not only Chairman of the Medical Commission of the Contergan Foundation, which judges whether a victim is or is not damaged by Contergan and also evaluates the degree of damage – on the basis of which the amount of the Contergan pension is assessed, for example. Since the Contergan trial, Wartensleben acted again and again as the legal representative of Grunenthal in cases relating to Contergan; most recently in 2007 in the lawsuits concerning the two-part ARD feature film "Eine einzige Tablette" (One single tablet).

"The case deals with the question of whether the Contergan Foundation was, or perhaps still is, an undercover subsidiary of Grunenthal under the eyes of the Federal Government," said Meyer.

Meyer will be represented by Prof. Dr. Jan Hegemann from the law firm Raue Rechtsanwälte LLP in Berlin. Attorney Prof. Dr. Jan Hegemann already successfully represented Meyer in 2009 in the case of Meyer's call to boycott the products of Dalli-Werke, Mäurer & Wirtz and 4711 – companies belonging to Grunenthal's owner. Attorney Karl Schucht will be represented by Attorneys Gernot Lehr and Tobias Würkert LLM from the Bonn office of the law firm Redeker Sellner Dahs. For Meyer, this is significant. The founder of that law firm, Prof. Dr. Hans Dahs senior who died in 1972, represented the late owner of Grunenthal, Dr. Hermann Wirtz senior, in the Contergan trial.

Place and date of the court hearing
Date: 15.2.2017
Time: 12:00 hrs
Place: Bonn Regional Court, Wilhelmstrasse 21, 53111 Bonn
Room: Courtroom S. 0.15 (Saalbau)
You can find further important information at the following link:
http://www.gruenenthal-opfer.de/Materials_Meyer_vs_Schucht_15_2_2017
Contact:
Federation of Thalidomide Sufferers and Grunenthal Victims
c/o Mr Andreas Meyer (Chairman)
Dohmengasse 7 , 50829 Koln
Email: bcg-brd-dachverband@gmx.de
Website: http://www.Gruenenthal-opfer.de
Mobile: +49 (0)172 / 2905974
Source: Federation of Thalidomide Sufferers and Grunenthal Victims

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics